Barclays raised the firm’s price target on Iqvia (IQV) to $185 from $165 and keeps an Equal Weight rating on the shares following the Q2 report. Barclays says that while Iqvia’s bookings beat expectations, it is not ready to call the bottom yet on biotechs.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IQV: